SecBot SecBot

LNTH

Lantheus Holdings, Inc.
Nasdaq· In Vitro & In Vivo Diagnostic Substances· Inc. DE· CIK 0001521036 Biotech & Drug Discovery
$100.10 +0.18 (+0.18%)
Oct 27 4:00 PM ET · prev $99.92
Market cap
$6.5B
Mid cap
Consensus
Buy
50% Buy or better · 16 analysts
Median target
$105.20
+5% · range $102.50–115.00
Next earnings
Oct 29
in 2 days
1 year
+72.2%
from $58.13 · Oct 27
30 days
+0.4%
from $99.74
52-week range
$50.69–110.94
−10% from high · low Nov 10
Avg volume 20D
1.00M
shares / day
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
1
Q2 2026 13F · 3 exits
Filing reports
13
analyzed by SecBot
SecBot read BULLISH 10 reports · 90 days
Balance 0 bearish · 6 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 10/10 ·Next Earnings date, Oct 29, 2026
Strongest NEUTRAL Lantheus disclosed that it and acquirer Curium US Holdings each received a Second Request from the FTC on…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 35 added (1 new), 33 trimmed or exited. Largest new: Holocene Advisors $60.7M.

  • AnalystsBULLISH

    8 of 16 rate it Buy or better. Every target is above the price.

  • TrendDOWNTREND

    0% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
3
exits
$60.7M
in new stakes
FundMoveSharesValue
AMERICAN CENTURY COMPANIES INCADD2,816,547$312.5M
PRICE T ROWE ASSOCIATES INC /MD/DOUBLED1,903,354$211.2M
CITADEL ADVISORS LLCDOUBLED1,376,480$152.7M
WELLINGTON MANAGEMENT GROUP LLPADD1,013,063$112.4M
BROWN ADVISORY INCADD915,683$101.6M
GOLDMAN SACHS GROUP INCADD814,096$90.3M
MARSHALL WACE, LLPADD773,978$85.9M
Assenagon Asset Management S.A.DOUBLED714,980$79.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 50% rate it Buy or better
Strong Buy2Buy6Hold8Sell0Strong Sell0
12-month targets · 8 analysts

Price is below the lowest target. Median implies +5%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 13, 2026Mizuho
DOWNGRADE
DOWNGRADENeutral
Aug 4, 2026Truist Securities
DOWNGRADE
DOWNGRADEHold
Aug 4, 2026CJS Securities
DOWNGRADE
DOWNGRADEMarket Perform
Aug 3, 2026William Blair
DOWNGRADE
DOWNGRADEMarket Perform
Aug 3, 2026TD Cowen
DOWNGRADE
DOWNGRADEHold
Jul 29, 2026Mizuho
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Aug 31, 2026
Marshall Robert J. Jr.
CFO and Treasurer
TAX W/H$72.8K
Aug 17, 2026
Brown Kimberly
Chief Accounting Officer
TAX W/H$46.7K
Aug 17, 2026
Dinkelborg Ludger
See Remarks
TAX W/H$255.9K
May 14, 2026
Morrow Phuong Khanh
Director
AWARD4,137 sh
May 14, 2026
McHugh Julie
Director
AWARD4,137 sh
May 14, 2026
EASTLAND JULIA MARIE
Director
AWARD4,137 sh
May 14, 2026
LENO SAM R
Director
AWARD4,137 sh
May 14, 2026
Pruden Gary J
Director
AWARD4,137 sh

Earnings setup

Estimates
Oct 29
reports in 2 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

7 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Aug 3, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
Lantheus disclosed that it and acquirer Curium US Holdings each received a Second Request from the FTC on October 21…
8-K — Impact 5/10
Oct 2, 2026 SEC
Lantheus Holdings filed a DEFA14A providing supplemental disclosures to its definitive proxy statement for the special…
DEFA14A — Impact 4/10
Oct 2, 2026 SEC
Lantheus filed an 8-K disclosing supplemental proxy disclosures to settle three shareholder lawsuits and 16 demand…
8-K — Impact 4/10
Sep 28, 2026 Other
Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer
Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prosta
Aug 31, 2026 Insider
Marshall Robert J. Jr. surrendered for taxes 721 shares
CFO and Treasurer @ $100.96 ($72.8K)
Aug 17, 2026 Insider
Brown Kimberly surrendered for taxes 463 shares
Chief Accounting Officer @ $100.91 ($46.7K)
Aug 17, 2026 Insider
Dinkelborg Ludger surrendered for taxes 2,536 shares
See Remarks @ $100.91 ($255.9K)
Aug 14, 2026 Press
Lantheus received FDA approval for TAUKLARIFY (florquinitau F 18), a tau PET imaging agent for evaluating Alzheimer's…
Impact 7/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Oct 29, 2026
Earnings date
LNTH Q3 2026 Earnings Before Market Open — 2026-10-29
Recent
Sep 28, 2026
Press release
Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer
Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancer Study advances development of…
Aug 14, 2026
FDA
Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease
BEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading…
Aug 13, 2026
FDA decision date
PDUFA: LNTH — MK-6240 in Unknown — 2026-08-13
FDA target action date 2026-08-13 for LNTH (Lantheus Holdings, Inc.). Drug: MK-6240. Indication: Unknown. PDUFA target action date set for MK-6240.
Aug 6, 2026
Earnings
Lantheus Reports Second Quarter 2026 Financial Results
BEDFORD, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading…
Aug 6, 2026
Earnings date
LNTH Q2 2026 Earnings Before Market Open — 2026-08-06

SecBot reports

13 filings · 3 press releases · 5 bullish · 0 bearish · 2 mixed · 6 neutral
All LNTH filing & press-release reports (16)